Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors
Authors:
- Larry K. KvolsLKLarry K. Kvols
- Eugene A. WolteringEWEugene A. Woltering
- 1 July 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 17 (6) , 601-608
Abstract
The somatostatin analogs octreotide, lanreotide and RC-160 (vapreotide) are known to have direct and indirect antitumor effects. Direct effects include the arrest of tumor growth and stimulation of apoptosis, resulting in tumor shrinkage. Indirect antiproliferative effects may occur through antiangiogenesis, immunomodulatory effects and the suppression of tumor-stimulating growth factors. With a safety profile of somatostatin analogs established over 20 years of clinical use in the treatment of neuroendocrine tumors, somatostatin analogs are attractive therapeutic options for patients with non-neuroendocrine tumors. In early clinical trials of somatostatin analogs, however, some cancer patients responded well, while others showed a lack of benefit. This variability in clinical response may reflect the selective binding affinities of octreotide, lanreotide and RC-160, which bind with high affinity to just two of the five different somatostatin receptor subtypes. Treatment response may therefore depend on the specific receptor subtype(s) present in the tumor, the relative proportion of receptor(s) expressed on the tumor cell surface and the absolute quantity of each receptor subtype. Greater understanding of the role of somatostatin receptors, their binding affinities and modes of action has led to increased research into the use of somatostatin analogs, particularly octreotide, in cancer treatment as monotherapies, in combination with hormonal treatments and cytotoxic therapies, and in both adjuvant and neoadjuvant settings. A review of the literature suggests that the antitumor potential of somatostatin analogs should be investigated further and additional studies might determine how these analogs can best be used to improve the treatment of patients with non-neuroendocrine tumors.Keywords
This publication has 73 references indexed in Scilit:
- Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenograftsJournal of Cancer Research and Clinical Oncology, 2003
- Effect of Somatostatin and Octreotide on Proliferation and Vascular Endothelial Growth Factor Secretion from Murine Endothelial Cell Line (HECa10) CultureBiochemical and Biophysical Research Communications, 2000
- Induction of Apoptosis in Neuroendocrine Tumors of the Digestive System During Treatment with Somatostatin AnalogsActa Oncologica, 1997
- Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotideSurgery, 1996
- Low-Dose Octreotide Treatment Is Not Effective in Patients with Advanced Pancreatic CancerPancreas, 1993
- Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implicationsThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- Treatment of the Malignant Carcinoid SyndromeNew England Journal of Medicine, 1986
- SomatostatinNew England Journal of Medicine, 1983
- SomatostatinNew England Journal of Medicine, 1983
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982